Cargando…
Molecular Networking for Drug Toxicities Studies: The Case of Hydroxychloroquine in COVID-19 Patients
Using drugs to treat COVID-19 symptoms may induce adverse effects and modify patient outcomes. These adverse events may be further aggravated in obese patients, who often present different illnesses such as metabolic-associated fatty liver disease. In Rennes University Hospital, several drug such as...
Autores principales: | Ferron, Pierre-Jean, Le Daré, Brendan, Bronsard, Julie, Steichen, Clara, Babina, Elodie, Pelletier, Romain, Hauet, Thierry, Morel, Isabelle, Tarte, Karin, Reizine, Florian, Clément, Bruno, Fromenty, Bernard, Gicquel, Thomas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8744768/ https://www.ncbi.nlm.nih.gov/pubmed/35008505 http://dx.doi.org/10.3390/ijms23010082 |
Ejemplares similares
-
Arylcyclohexylamine Derivatives: Pharmacokinetic, Pharmacodynamic, Clinical and Forensic Aspects
por: Pelletier, Romain, et al.
Publicado: (2022) -
Toxic Effects of Amanitins: Repurposing Toxicities toward New Therapeutics
por: Le Daré, Brendan, et al.
Publicado: (2021) -
New insights into quetiapine metabolism using molecular networking
por: Le Daré, Brendan, et al.
Publicado: (2020) -
Treatments in Covid-19 patients with pre-existing metabolic dysfunction-associated fatty liver disease: A potential threat for drug-induced liver injury?
por: Ferron, Pierre-Jean, et al.
Publicado: (2020) -
A Transversal Approach Combining In Silico, In Vitro and In Vivo Models to Describe the Metabolism of the Receptor Interacting Protein 1 Kinase Inhibitor Sibiriline
por: Pelletier, Romain, et al.
Publicado: (2022)